Somatostatin receptor gene transfer inhibits established pancreatic cancer xenografts

Journal of Surgical Research

Volumn 115, Issue 1, 2003, Pages 41-47

  Celinski, Scott A ^a   Fisher, William E ^a   Amaya, Felipe ^a   Wu, Yuan Qing ^a   Yao, Q ^a   Youker, Keith A ^a   Li, Min ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Gene therapy; Pancreatic adenocarcinoma; Somatostatin receptors

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; OCTREOTIDE; PROTEIN P16; PROTEIN P27; SOMATOSTATIN RECEPTOR; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CANCER SURGERY; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GROWTH RATE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOMATOSTATIN BLOOD LEVEL; TISSUE CULTURE CELL; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING; XENOGRAFT;

EID: 0142218032     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-4804(03)00276-2     Document Type: Article

References (22)

1. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics, 1999. CA Cancer J. Clin. 49:1999;8.
2. Schaly A.V. Oncological applications of somatostatin analogues. Cancer Res. 48:1992;69.
3. Redding T.W., Schally A.V. Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. Proc. Natl. Acad. Sci. USA. 81:1984;248.
4. Paz-Bouza J.I., Redding T.W., Schally A.V. Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogs of somatostatin and lutenizing hormone-releasing hormone. Proc. Natl. Acad. Sci. 84:1987;1112.
5. Zalatnai A., Schaly A.V. Treatment of N-Nitrosobis(2-oxopropyl)amine- induced pancreatic cancer in Syrian golden hamsters with D-Trp-6-LH-RH and somatostatin analogue RC-160 microcapsules. Cancer Res. 49:1989;1810.
6. Van Eijck C.H.J., Lamberts S.W.J., Lemaire L.C.J.M., Jeekel H., Bosman F.T., Reubi J.C., Bruining H.A., Krenning E.P. The use of somatostatin receptor scintigraphy in the differential diagnosis of pancreatic duct cancers and islet cell tumors. Ann. Surg. 224:1996;119.
7. Reubi J.C., Horisberger U., Essed C.E., Jeekel J., Klijn J.G., Lamberts S.W. Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas. Gastroenterology. 95:1988;760.
8. Fekete M., Zalatnai A., Comaru-Schally A.M., Schally A.V. Membrane receptors for peptides in experimental and human pancreatic cancers. Pancreas. 4:1989;521.
9. Srkalovic G., Ren-Zhi C., Schally A.V. Evaluation of receptors for somatostatin in various tumors using different analogs. J. Clin. Endocrinol. Metab. 70:1990;661.
10. Klijn J.G.M., Hoff A.M., Th A.S., Planting J., Verweij T., Kok T., Lamberts S.W., Portengen H., Foekens J.A. Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin A phase II study including endocrine effects. Br. J. Cancer. 62:1990;627.
11. Canobbio L., Boccardo F., Cannata D., Gallotti P., Epis R. Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Cancer. 69:1992;648.
12. Huguier M., Samama G., Testart J., Mauban S., Fingerhut A., Nassar J., Houry S., Jaeck D., De Mestier P., Favre J.P., Michot F., Vidrequin A., Mantion G., Veyrieres M., Fourtainier G., Lointer P., Gignoux M. Treatment of adenocarcinoma of the pancreas with somatostatin and gonadoliberin (lutenizing hormone-releasing hormone). Am. J. Surg. 164:1992;348.
13. Davis A.R., Meyers K., Wilson J.M. High throughput method for creating and screening recombinant adenoviruses. Gene Ther. 5:1998;1148.
14. Sharma K., Patel Y.C., Srikant C.B. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol. Endocrinol. 10:1996;1688.
15. Sharma K., Patel Y.C., Srikant C.B. C-terminal region of human somatostatin receptor 5 is required for induction of Rb and G1 cell cycle arrest. Mol. Endocrinol. 13:1999;82.
16. Pages P., Buscail L., Delesque N., Saint Laurent N., Esteve J., Tkaczuk J., Schally A., Vaysse N., Susini C. G1 cell-cycle arrest and up-regulation of p27kip1 expression after activation of somatostatin sst2 receptor. Gastroenterology. 112:1997;635A.
17. Fisher W.E., Boros L.G., Tamaddon A.K., O'Dorisio T.M., O'Dorisio M.S., Schirmer W.J. Somatostatin-receptor status of pancreatic adenocarcinoma predicts response to somatostatin therapy in vitro and in vivo. Surg. Forum. 46:1995;137.
18. Fisher W.E., Muscarella P., O'Dorisio T.M., O'Dorisio M.S., Kim J.A., Doran T.A., Sabourin C.L., Schirmer W.J. Expression of the somatostatin receptor subtype-2 gene predicts response of human pancreatic cancer to octreotide. Surgery. 120:1996;234.
19. Fisher W.E., Wu Y., Amaya F., Berger D.H. Somatostatin receptor subtype 2 gene therapy inhibits pancreatic cancer in vitro. J. Surg. Res. 105:2002;58.
20. Delesque N., Buscail L., Esteve J.P., Saint-Laurent N., Muller C., Weckbecker G., Bruns C., Vaysse N., Susini C. SST2 Somatostatin receptor expression reverses tumorigenicity of human pancreatic cancer cells. Cancer Res. 57:1997;956.
21. Fisher W.E., Doran T.A., Muscarella P., Boros L.G., Ellison E.C., Schirmer W.J. Expression of somatostatin receptor subtype 1-5 genes in human pancreatic cancer. JNCI. 90:1998;322.
22. Torrisani J., Bouisson M., Puente E., Capella G., Laurent-Puig P., Berger A., Vaysse N., Susini C., Buscail L. Transcription of SST2 somatostatin receptor gene in human pancreatic cancer cells is altered by single nucleotide promoter polymorphism. Gastroenterology. 120:2001;200.